<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383119</url>
  </required_header>
  <id_info>
    <org_study_id>ISG-ARTICLE</org_study_id>
    <nct_id>NCT04383119</nct_id>
  </id_info>
  <brief_title>Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma</brief_title>
  <acronym>ISG-ARTICLE</acronym>
  <official_title>A Randomized Phase II Trial Comparing the Activity of trabectedIn vs Gemcitabine in Patients With Metastatic or Locally Advanced Leiomyosarcoma Pretreated With Conventional Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study is aimed at evaluating the activity of Trabectedin (arm A) in advanced leiomyosarcomas,
      having Gemcitabine (arm B) as the comparator.

      In parallel an optional translational study will be performed to identify factors predictive
      of the activity of Trabectedin or Gemcitabine in this specific histotype.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The management of patients with leiomyosarcomas determines many difficulties. Despite
      patients with metastatic disease at diagnosis or who recur after initial treatment have a
      dismal prognosis and, except for a subset of selected patients with completely resectable
      disease, the median survival is less than two years.

      At the advanced-disease stage, the main aim of treatment is to improve patient's quality of
      life, possibly survival, with the best compromise between toxicity and symptoms. Trabectedin
      (T) is a marine-derived cytotoxic approved by European MEdicine Agency (EMEA) and FDA.

      It is indicated for the treatment of patients with advanced soft tissue sarcoma, after
      failure of anthracyclines-based chemotherapy or who are unsuitable to receive these agents.

      Among Soft Tissue Sarcoma (STS), activity has been mainly detected in synovial sarcoma,
      liposarcoma and leiomyosarcoma. Although the response rate did not exceed 10%, T was
      demonstrated to provide disease control, with progression arrest rates exceeding 50% and
      progression-free survival rates exceeding 20% at 6 months. So far no phase II or III studies
      have been addressed to test the activity of T in leiomyosarcoma specifically (without
      differentiation between site of primary localization) in comparison with Gemcitabine.

      This study is aimed at evaluating the activity of Trabectedin (arm A) in advanced
      leiomyosarcomas, having Gemcitabine (arm B) as the comparator. In parallel an optional
      translational study will be performed to identify factors predictive of the activity of
      Trabectedin or Gemcitabine in this specific histotype.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>multicenter, randomized, open-label, two arms with crossover. Patients will be randomized to receive Trabectedin (arm A) or Gemcitabine (arm B).
In case of progressive disease (PD) or unacceptable toxicity during the assigned treatment, the patient will switched to the other arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Not applicable (open label study)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the Growth Modulation Index (GMI) in patients treated with Trabectedin or Gemcitabine</measure>
    <time_frame>Week 6, week 12, week 18, week 27, week 36 and week 45</time_frame>
    <description>Ratio of Time To Progression with the Mth line (TTPn) of therapy to the TTPn−1 with the n-1th line.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Week 6, week 12, week 18, week 27, week 36 and week 45</time_frame>
    <description>Overall response rate according Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years and 5 years</time_frame>
    <description>Survival from the first dose treatment to death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free Survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>Survival without disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Week 6, week 12, week 18, week 27, week 36 and week 45</time_frame>
    <description>Duration of tumor control according Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to the treatment</measure>
    <time_frame>Week 3, week 6, week 9, week 12, week 18, week 27, week 36, week 45</time_frame>
    <description>Safety in term of adverse event is evaluate from the first treatment dose throughout the study according to CTCAE 5.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory objectives</measure>
    <time_frame>week 6, and at up to week 53</time_frame>
    <description>Identify gene mutations that may be associated to response/resistance to the treatment and to clinical outcomes parameters.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Leiomyosarcoma of Ovary</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trabectedin at the dose of 1.5 mg/m2-1.3 mg/m2 with a top-dose of 2.6 total mg per cycle (according the clinical practice in pretreated patients and in all our ISG studies) will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine 800-1000 mg/m2 will be administered via a central venous catheter on days 1,8 every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <description>Trabectedin in monotherapy</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Trabectedin arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine, control arm</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Gemcitabine arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically documented diagnosis of leiomyosarcoma

          2. Patients with diagnosis of unresectable or metastatic leiomyosarcoma

          3. Patients who received at least on previous systemic treatment with anthracycline-based
             chemotherapy.

          4. Patients suitable to receive gemcitabine or trabectedin therapy.

          5. Measurable or evaluable disease with RECIST 1.1 criteria.

          6. Evidence of progression according RECIST 1.1 during the 6 months before study entry.

          7. Age ≥18 years

          8. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2

          9. All previous anticancer treatments must have completed ≥ 3 weeks prior to first dose
             of study drug.

         10. The patient has resolution of adverse events, with the exception of alopecia, and of
             all clinically significant toxic effects of prior loco-regional therapy, surgery,
             radiotherapy or systemic anticancer therapy to ≤ Grade 1, by National Cancer Institute
             - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0

         11. Adequate bone marrow, liver and renal function

         12. Left Ventricular Ejection Fraction ≥ 50% and/or above lower institutional limit of
             normality.

         13. Female patients of child-bearing potential must have negative pregnancy test within 7
             days before initiation each cycle of chemotherapy.

         14. No history of arterial and/or venous thromboembolic event within the previous 12
             months.

         15. The patient or legal representative must be able to read and understand the informed
             consent form and must have been willing to give written informed consent prior to any
             study specific procedure. The subject may also provide an optional consent for the
             biological/translational sub-study associated.

        Exclusion Criteria:

          1. Prior treatment with Trabectedin and/or Gemcitabine

          2. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in
             the formulation of the study drugs

          3. History of other malignancies (except basal cell carcinoma or cervical carcinoma in
             situ, adequately treated), unless in remission from 5 years or more and judged of
             negligible potential of relapse.

          4. Persistent toxicities with the exception of alopecia, caused by previous anticancer
             therapies

          5. Metastatic brain or meningeal tumors

          6. Active viral hepatitis

          7. Immunocompromised patients, e.g., patients who are known to be serologically positive
             for human immunodeficiency virus

          8. Patients with any severe and/or uncontrolled medical conditions

          9. Medical history of hemorrhage or a bleeding event ≥ Grade 3 (NCI-CTCAE v 5.0) within 4
             weeks prior to the initiation of study treatment

         10. Active clinically serious infections

         11. Immunocompromised patients, e.g., patients who are known to be serologically positive
             for human immunodeficiency virus

         12. Previous treatment with radiation therapy within 14 days of first day of study drug
             dosing,

         13. Major surgery within 4 weeks prior to study entry

         14. Concomitant use of known strong CYP3A inhibitors or moderate CYP3A inhibitors

         15. Concomitant use of known strong or moderate CYP3A inducers

         16. Patients undergoing renal dialysis or with Creatinin Clearance &lt;30 ml/min or
             Creatinine &gt;1,5 mg/dL

         17. Pregnant or breast feeding patients

         18. Patients with severe and/or uncontrolled concurrent medical disease that in the
             opinion of the investigator could cause unacceptable safety risks or compromise
             compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Vincenzi, Prof/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Campus Biomedico of Rome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Vincenzi, Prof/MD</last_name>
    <phone>003906-22541</phone>
    <phone_ext>1123</phone_ext>
    <email>b.vincenzi@unicampus.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emanuela Marchesi, PhD</last_name>
    <phone>003905101459</phone>
    <phone_ext>78</phone_ext>
    <email>emanuela.marchesi@italiansarconmagroup.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Abbondanza Pantaleo, MD</last_name>
      <phone>+39 051 2144043</phone>
      <email>maria.pantaleo@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Maria Abbondanza Pantaleo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Toni Ibrahim, MD</last_name>
      <phone>0039054373</phone>
      <phone_ext>9100</phone_ext>
      <email>toni.ibrahim@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Toni Ibrahim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale di Prato</name>
      <address>
        <city>Prato</city>
        <state>Firenze</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giacomo G. Baldi, MD</last_name>
      <phone>0039057443</phone>
      <phone_ext>4766</phone_ext>
      <email>giacomogiulio.baldi@uslcentro.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Giacomo G. Baldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexia Bertuzzi, MD</last_name>
      <phone>+390282244540</phone>
      <email>alexia.bertuzzi@cancercenter.humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Alexia Bertuzzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico di Aviano</name>
      <address>
        <city>Aviano</city>
        <state>PD</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Angela Buonadonna, MD</last_name>
      <phone>+39 0434 659190</phone>
      <email>abuonadonna@cro.it</email>
    </contact>
    <investigator>
      <last_name>Angela Buonadonna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno Vincenzi, MD</last_name>
      <phone>+3902225411123</phone>
      <email>b.vincenzi@unicampus.it</email>
    </contact>
    <investigator>
      <last_name>Bruno Vincenzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.R.C.C. - Unit of Medical Oncology</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giovanni Grignani, MD</last_name>
      <phone>+39.011.9933</phone>
      <phone_ext>278</phone_ext>
      <email>giovanni.grignani@ircc.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Grignani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Alessandra Longhi, MD</last_name>
      <phone>+390516366</phone>
      <phone_ext>199</phone_ext>
      <email>alessandra.longhi@ior.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Longhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS INT Milano</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Roberta Sanfilippo, MD</last_name>
      <phone>+390223903</phone>
      <phone_ext>468</phone_ext>
      <email>roberta.sanfilippo@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Roberta Sanfilippo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Oncologico Veneto (Iov)</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonella Brunello, MD</last_name>
      <phone>0039049 8215</phone>
      <phone_ext>910</phone_ext>
      <email>antonella.brunello@ioveneto.it</email>
    </contact>
    <investigator>
      <last_name>Antonella Brunello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Giaccone</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giuseppe Giuseppe, MD</last_name>
      <email>giuseppe.badalamenti@unipa.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Giuseppe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena - IFO</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Virginia Ferraresi, MD</last_name>
      <phone>+39065266919</phone>
      <email>ferraresi@ifo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASL Città di Torino (Dipartimento di Oncologia)</name>
      <address>
        <city>Torino</city>
        <zip>10153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Alessandro Comandone, MD</last_name>
      <email>alessandro.comandone@aslcittaditorino.it</email>
    </contact>
    <contact_backup>
      <last_name>Boglione, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Alessandro Comandone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015 Apr 1;33(10):1180-5. doi: 10.1200/JCO.2014.58.3781. Epub 2015 Feb 23.</citation>
    <PMID>25713428</PMID>
  </reference>
  <reference>
    <citation>Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, Cupissol D, Selle F, Isambert N, Piperno-Neumann S, Thyss A, Bertucci F, Bompas E, Alexandre J, Collard O, Lavau-Denes S, Soulié P, Toulmonde M, Le Cesne A, Lacas B, Duffaud F; French Sarcoma Group. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2015 Apr;16(4):457-64. doi: 10.1016/S1470-2045(15)70070-7. Epub 2015 Mar 18.</citation>
    <PMID>25795402</PMID>
  </reference>
  <reference>
    <citation>Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009 Sep 1;27(25):4188-96. doi: 10.1200/JCO.2008.21.0088. Epub 2009 Aug 3.</citation>
    <PMID>19652065</PMID>
  </reference>
  <reference>
    <citation>Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001 Aug 1;19(15):3483-9.</citation>
    <PMID>11481354</PMID>
  </reference>
  <reference>
    <citation>Pautier P, Floquet A, Penel N, Piperno-Neumann S, Isambert N, Rey A, Bompas E, Cioffi A, Delcambre C, Cupissol D, Collin F, Blay JY, Jimenez M, Duffaud F. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist. 2012;17(9):1213-20. Epub 2012 Aug 20.</citation>
    <PMID>22907974</PMID>
  </reference>
  <reference>
    <citation>Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4.</citation>
    <PMID>28882536</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced leiomyosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not applicable no plan to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

